These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 138101)
61. Normal excretion of homovanillic acid in the urine of patients with Huntington's chorea. WILLIAMS CM; MAURY S; KIBLER RF J Neurochem; 1961 Feb; 6():254-6. PubMed ID: 13785404 [No Abstract] [Full Text] [Related]
62. Hyperglycemic chorea-ballism or acute exacerbation of Huntington's chorea? Huntington's disease unmasked by diabetic ketoacidosis in type 1 diabetes mellitus. Hashimoto K; Ito Y; Tanahashi H; Hayashi M; Yamakita N; Yasuda K J Clin Endocrinol Metab; 2012 Sep; 97(9):3016-20. PubMed ID: 22745234 [TBL] [Abstract][Full Text] [Related]
63. [Effect of administration of amino acids, especially of L-DOPA and -methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. 3. Alterations of cerebrospinal fluid in patients with Huntington's chorea after -methyldopa or L-DOPA]. Simanyi M; Gerstenbrand F; Gründig E; Schedl R; Weiss H Z Neurol; 1973 Mar; 204(1):67-80. PubMed ID: 4121504 [No Abstract] [Full Text] [Related]
64. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329 [TBL] [Abstract][Full Text] [Related]
65. Test for incipient Huntington's chorea. Cawein M; Turney F N Engl J Med; 1971 Mar; 284(9):504. PubMed ID: 4250751 [No Abstract] [Full Text] [Related]
66. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461 [TBL] [Abstract][Full Text] [Related]
67. Juvenile Huntington's disease: a case report and literature review. Reyes Molón L; Yáñez Sáez RM; López-Ibor Alcocer MI Actas Esp Psiquiatr; 2010; 38(5):285-94. PubMed ID: 21117003 [TBL] [Abstract][Full Text] [Related]
68. Controlled trial of sodium valproate in severe epilepsy. Richens A; Ahmad S Br Med J; 1975 Nov; 4(5991):255-6. PubMed ID: 1104059 [TBL] [Abstract][Full Text] [Related]
69. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment? Lin F; Qin ZH J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512 [TBL] [Abstract][Full Text] [Related]
70. The long-term effect of tetrabenazine in the management of Huntington disease. Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408 [TBL] [Abstract][Full Text] [Related]
71. [Several biochemical mechanisms of the pathogenesis of Huntington chorea]. Barkhatova VP; Larskiĭ EG; Markova ED; Ivanova-Smolenskaia IA; Insarova NG Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(7):1038-45. PubMed ID: 6137919 [TBL] [Abstract][Full Text] [Related]
73. Effects of dipropylacetic acid on late components of the photically evoked potential and afterdischarge in rat. Shearer DE; Fleming DE; Dustman RE Pharmacol Biochem Behav; 1978 Apr; 8(4):501-4. PubMed ID: 353820 [TBL] [Abstract][Full Text] [Related]
74. Investigation in the dipropylacetic acid series, C8 and C9 branched chain ethylenic acids and amides. Taillandier G; Benoit-Guyod JL; Laruelle C; Boucherle A Arch Pharm (Weinheim); 1977 May; 310(5):394-403. PubMed ID: 326226 [No Abstract] [Full Text] [Related]